Legal status | |
---|---|
Legal status | |
Identifiers | |
IUPAC name
| |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H25N3O |
Molar mass | 347.462 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Germany in February 2020. It is illegal in Finland.
See also
References
- Haschimi B, Grafinger KE, Pulver B, Psychou E, Halter S, Huppertz LM, et al. (August 2021). "New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA". Drug Testing and Analysis. 13 (8): 1499–1515. doi:10.1002/dta.3038. PMID 33788409.
- "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.
- "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista" [Government Decree on psychoactive substances banned from the consumer market]. Finlex (in Finnish). Finnish Ministry of Justice.
Cannabinoid receptor modulators | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Receptor (ligands) |
| ||||||||||||||||||||||||||||||
Transporter (modulators) |
| ||||||||||||||||||||||||||||||
Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||||||||
|
This cannabinoid related article is a stub. You can help Misplaced Pages by expanding it. |